Clincosm LogoSign in Get a demo

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Sponsor
Boehringer Ingelheim (Industry)
Overall Status
Completed
CT.gov ID
NCT03817476
Collaborator
(none)
18
Enrollment
1
Location
6
Arms
3.5
Actual Duration (Months)
5.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main objective of this trial is to investigate the relative bioavailability of batch 1 of the intended commercial tablet formulation (iCF1) of BI 425809 vs batch 2 of the intended commercial tablet formulation (iCF2) of BI 425809 vs BI 425809 (TF2) formulation.

Condition or Disease Intervention/Treatment Phase
  • Drug: BI 425809 (Treatment T1)
  • Drug: BI 425809 (Treatment T2)
  • Drug: BI 425809 (Treatment R)
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
18 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Relative Bioavailability of Batch 1 and Batch 2 of the Intended Commercial Formulation of BI 425809 Compared to Each Other and to TF 2 Formulation of BI 425809 Following Oral Administration in Healthy Male and Female Subjects (Randomized, Open-label, Single-dose, Three-treatment, Three-period, Six-sequence Crossover Study)
Actual Study Start Date :
Feb 11, 2019
Actual Primary Completion Date :
May 28, 2019
Actual Study Completion Date :
May 28, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: T1-T2-R

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)
Experimental: T1-R-T2

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)
Experimental: T2-T1-R

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)
Experimental: T2-R-T1

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)
Experimental: R-T1-T2

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)
Experimental: R-T2-T1

Drug: BI 425809 (Treatment T1)
Intended commercial formulation tablet from batch 1 (iCF1)

Drug: BI 425809 (Treatment T2)
Intended commercial formulation tablet from batch 2 (iCF2)

Drug: BI 425809 (Treatment R)
Trial formulation 2 tablet (TF2)

Outcome Measures

Primary Outcome Measures

  1. AUC0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 h) [Up to 72 hours]

  2. Cmax (maximum measured concentration of the analyte in plasma) [Up to 72 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests

  • Age of 18 to 55 years (inclusive)

  • Body Mass Index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)

  • Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation

  • Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:

  • Use of adequate contraception, e.g. any of the following methods plus condom:

--- implants, injectables, combined oral or vaginal contraceptives, intrauterine device

  • Sexually abstinent

  • A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)

  • Surgically sterilised (including hysterectomy)

  • Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with levels of FSH above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion Criteria:

  • Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator

  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)

  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance

  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)

  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

  • History of relevant orthostatic hypotension, fainting spells, or blackouts

  • Chronic or relevant acute infections

  • History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)

  • Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)

  • Intake of an investigational drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered

  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

  • Inability to refrain from smoking on specified trial days

  • Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)

  • Drug abuse or positive drug screening

  • Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial

  • Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial

  • Inability to comply with the dietary regimen of the trial site

  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females) or any other relevant Electrocardiogram (ECG) finding at screening

  • A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)

  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

  • Female subjects, only: Positive pregnancy test, pregnancy, or plans to become pregnant within 30 days after study completion

  • Female subjects, only: Lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Humanpharmakologisches Zentrum Biberach Biberach Germany 88397

Sponsors and Collaborators

  • Boehringer Ingelheim

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT03817476
Other Study ID Numbers:
  • 1346-0019
  • 2018-003625-29
First Posted:
Jan 25, 2019
Last Update Posted:
Jun 4, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
BI 425809

Study Results

No Results Posted as of Jun 4, 2019